- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Royalty Pharma Plc (RPRX)
Royalty Pharma Plc stock price live, this page displays NASDAQ RPRX stock exchange data. View the RPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Royalty Pharma Plc real time stock price chart below.
What Is the Royalty Pharma Plc Stock Price Today?
The Royalty Pharma Plc stock price today is 66.25.
What Is the Stock Symbol for Royalty Pharma Plc?
The stock symbol for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RPRX quote. (ISIN: GB00BMVP7Y09)
What Is the Royalty Pharma Plc Stock Price Today?
The Royalty Pharma Plc stock price today is 66.25.
What Is the Stock Symbol for Royalty Pharma Plc?
The stock symbol for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RPRX quote. (ISIN: GB00BMVP7Y09)
66.25
-0.16(-0.23%)
Real-time Data·
Fair Value
An estimate of a Royalty Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.84
67.18
52 wk Range
36.03
67.71
Earnings results expected today
1/2
Fair Value
An estimate of a Royalty Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.8467.18
52 wk Range
36.0367.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RPRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Royalty Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
65.38
Downside
-1.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 65.38
(-1.32% Downside)
Royalty Pharma Plc Earnings Call Summary for Q3/2026
- Royalty Pharma Q3 EPS of $1.21 beat estimates by $0.03; revenue of $890M topped forecasts by $12.63M, though shares fell 1.81% in premarket.
- Portfolio receipts rose 9% YoY to $890M; company raised FY2026 guidance for third consecutive quarter, now expecting $3.5B-$3.55B in receipts.
- Royalty receipts grew 9% quarterly and 12% YTD, driven by TREMFYA, Voranigo, Evrysdi and IMDELLTRA despite declines in Promacta and IMBRUVICA.
- Management sees clear path to deploy $2.5B annually through synthetic royalties, R&D co-funding, and China expansion; announced $1B in 2026 deals.
- Operating costs fell to 5.6% of receipts post-internalization; portfolio cash flow margin reached 76% quarterly and 82% YTD with 95.82% gross margin.
Last Updated: 04/11/2026, 16:28
Read Full TranscriptEarnings
Latest Release
Nov 04, 2026
EPS / Forecast
1.21 / 1.18
Revenue / Forecast
890M / 877.37M
Compare RPRX to Peers and Sector
Metrics to compare | RPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 36.0x | 17.1x | −0.3x | |
PEG Ratio | −1.82 | −0.31 | 0.00 | |
Price/Book | 5.5x | 3.0x | 2.6x | |
Price / LTM Sales | 14.9x | 2.2x | 2.8x | |
Upside (Analyst Target) | −0.6% | 37.8% | 67.2% | |
Fair Value Upside | Unlock | 13.4% | 10.1% | Unlock |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Royalty Pharma (RPRX) Stock Price Today?
The Royalty Pharma stock price today is 66.25 USD.
What Stock Exchange Does Royalty Pharma Trade On?
Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Royalty Pharma?
The stock symbol for Royalty Pharma is "RPRX."
What Is the Royalty Pharma Market Cap?
As of today, Royalty Pharma market cap is 38.09B USD.
What Is Royalty Pharma's Earnings Per Share (TTM)?
The Royalty Pharma EPS (TTM) is 1.86.
From a Technical Analysis Perspective, Is RPRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Royalty Pharma Stock Split?
Royalty Pharma has split 0 times.
How Many Employees Does Royalty Pharma Have?
Royalty Pharma has 100 employees.
What is the current trading status of Royalty Pharma (RPRX)?
As of Nov 04, 2026, Royalty Pharma (RPRX) is trading at a price of 66.25 USD, with a previous close of 66.40 USD. The stock has fluctuated within a day range of 64.84 USD to 67.18 USD, while its 52-week range spans from 36.03 USD to 67.71 USD.
What Is Royalty Pharma (RPRX) Price Target According to Analysts?
The average 12-month price target for Royalty Pharma is 65.38 USD, with a high estimate of 70 USD and a low estimate of 61 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -1.32% Downside potential.
What Is the RPRX Premarket Price?
RPRX's last pre-market stock price is 66.00 USD. The pre-market share volume is 3,630.00, and the stock has decreased by -0.40, or -0.60%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.